publication venue for
- Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials.. 31. 2022
- An Expert Opinion on Methylphenidate Treatment for Attention Deficit Hyperactivity Disorder in Pediatric Patients with Epilepsy. 17:77-84. 2008
- The therapeutic potential of vasopressin receptor antagonists in congestive heart failure.. 14. 2005
- Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.. 13. 2004
- Therapeutic developments in amyotrophic lateral sclerosis.. 8. 1999
- Clinical trials report on ongoing trials in lung cancer.. 6. 1997
- Docetaxel: a new active agent in the therapy of metastatic breast cancer.. 6. 1997
- The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727.. 21. 2012
- Cancer immunotherapeutics meeting. 2004
- C-MET inhibitors for advanced non-small cell lung cancer. 2018
- Cefiderocol: a novel siderophore cephalosporin. 2018
- MEK inhibitors under development for treatment of non-small-cell lung cancer. 2017
- Drugs currently under investigation for the treatment of invasive candidiasis. 2017
- Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. 2014
- Have we reached the limits for the treatment of diabetic nephropathy? 2014
- IL-17 targeted therapies for psoriasis. 2013
- Small-molecule inhibitors of the human epidermal receptor family. 2009
- Corticorelin acetate injections for the treatment of peritumoral brain edema. 2009
- The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. 2008
- Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. 2007
- Sunitinib malate for the treatment of solid tumours: a review of current clinical data. 2006
- Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. 2004
- Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer. 2004
- Progesterone antagonists and progesterone receptor modulators. 2003
- Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study. 2003
- Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction. 2003
- Therapeutic potential of H(3)-receptor agonists in myocardial infarction. 2000
- Targeted therapies for the myeloid leukaemias. 2000
- Type I interferon antagonists in clinical development for lupus. 2020
- Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? 2020
- GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). 2019
- Drugs in early clinical development for Systemic Lupus Erythematosus. 2016
- Sirukumab : a novel therapy for lupus nephritis? 2014
- Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. 2009
- Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. 2009
- MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. 2005
- Novel therapeutic agents under investigation for malignant melanoma. 2003
- Recent advances in the pharmacological treatment of colorectal cancer. 2003